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Abstract
Background: Fibroblast Growth Factors (FGFs) represent a large family of secreted proteins that
are required for proper development and physiological processes. Mutations in mouse and
zebrafish FGFs result in abnormal embryogenesis and lethality. A key to understanding the precise
role for these factors is to determine their spatial and temporal activity during embryogenesis.
Results: Expression of Dual Specificity Phosphatase 6 (dusp6, also known as Mkp3) is controlled by
FGF signalling throughout development. The Dusp6 promoter was isolated from zebrafish and used
to drive expression of destabilized green fluorescent protein (d2EGFP) in transgenic embryos
(Tg(Dusp6:d2EGFP)). Expression of d2EGFP is initiated as early as 4 hours post-fertilization (hpf)
within the future dorsal region of the embryo, where fgf3 and fgf8 are initially expressed. At later
stages, d2EGFP is detected within structures that correlate with the expression of Fgf ligands and
their receptors. This includes the mid-hindbrain boundary (MHB), pharyngeal endoderm, otic
vesicle, hindbrain, and Kupffer's vesicle. The expression of d2EGFP is under the control of FGF
signalling as treatment with FGF Receptor (FGFR) inhibitors results in the suppression of d2EGFP
expression. In a pilot screen of commercially available small molecules we have evaluated the
effectiveness of the transgenic lines to identify specific FGF inhibitors within the class of
indolinones. These compounds were counter screened with the transgenic line Tg(Fli1:EGFP)y1, that
serves as an indirect read-out for Vascular Endothelial Growth Factor (VEGF) signalling in order to
determine the specificity between related receptor tyrosine kinases (RTKs). From these assays it
is possible to determine the specificity of these indolinones towards specific RTK signalling
pathways. This has enabled the identification of compounds that can block specifically the VEGFR
or the FGFR signalling pathway.
Conclusion: The generation of transgenic reporter zebrafish lines has allowed direct visualization
of FGF signalling within the developing embryo. These FGF reporter transgenic lines provide a tool
to screen for specific compounds that can distinguish between two conserved members of the RTK
family.
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Background
The complex process of embryogenesis is directed by the
regulation of signalling pathways that are achieved in part
by the activity of a variety of secreted ligands. Thus under-
standing the temporal and spatial activity of signalling
peptides is key to determining the role for these factors in
controlling cellular fates. For example, Fibroblast Growth
Factors (FGFs), a family of secreted glycoproteins, per-
form crucial functions that include the establishment of
embryo polarity, the formation of organizing centres, and
the induction of limb outgrowth [1-3]. These ligands are
expressed in discrete domains during development and
their actions are restricted to cells that express integral
membrane proteins that can bind FGFs [2,4]. The FGF
receptors (FGFRs) are members of the receptor tyrosine
kinase (RTK) class of transmembrane proteins and acti-
vate several signalling cascades, including the phospholi-
pase C gamma (PLC-γ), phosphatidylinositol-3 kinase
(PI3K) which activates Akt/protein kinase B, and Ras
which activates extracellular signal-regulated protein
kinase (ERK, also known as MAPK) pathways [5,6]. FGF
activity results in the control of gene expression through
the modification of transcription factors by activated ERKs
and AKT. As a consequence of altered gene expression, cel-
lular proliferation, survival and fate determination can be
governed by FGF activity. How FGFs control gene expres-
sion and the nature of the genes that they regulate during
development is still not completely established.
One step towards defining FGF target genes is to deter-
mine the temporal and spatial activity of FGFs during
development. This will provide an activity map of where
and when these factors act to control developmental proc-
esses. Since activation of FGF signalling results in the
phosphorylation of Erk, one approach to illustrate FGF
activity during development has been to detect the spatial
and temporal presence of phosphorylated ERKs in the
embryo. This has resulted in mapping the location of FGF
activity during mouse, chick, Xenopus laevis and zebrafish
embryogenesis [7-12]. While these studies provide a
detailed analysis of FGF activity during development, it is
not possible to visualize FGF activity in the live embryo
and observe the dynamic changes in FGF signalling as the
embryo develops.
We have previously identified several FGF regulated genes
in zebrafish, including the Dual Specificity Phosphatase 6,
dusp6 (also known as Map Kinase Phosphatase 3, mkp3), and
Sef, two genes that exhibit almost identical expression to
fgf8 and fgf3 during development [11,13-15]. Dusp6 func-
tions to dephosphorylate activated p44 and p42 ERKs and
over-expression of Dusp6 results in the suppression of
FGF activity in the embryo [11,16-18]. Expression of dusp6
was suppressed in embryos treated with SU5402, an FGFR
inhibitor, or by the ectopic expression of dominant nega-
tive FGFR, indicating that dusp6 transcription is regulated
by FGFs [11,16-18]. Genetic studies in mouse have iden-
tified the requirement for FGFRs in maintaining Dusp6
expression, as loss of either FGFR1 or FGFR2 resulted in
the depletion of Dusp6 transcripts [19]. It is clear from
these studies that Dusp6 expression is regulated by FGF lig-
ands and receptors, however it has been controversial as
to which signalling pathway downstream of the receptor
is required for Dusp6 gene transcription.
Experiments described in the chick, mouse and zebrafish
embryos have provided clues that Dusp6 gene regulation
is context dependent [11,16-18,20,21]. In several studies,
the PI3K inhibitor, LY294002, was used in the chick limb
bud to show that blocking the PI3K/AKT pathway results
in the suppression of Dusp6 expression within the distal
limb bud [17,20]. Likewise, implantation beads soaked in
LY294002 could suppress Dusp6  expression within the
mid-hindbrain boundary (MHB) in mouse and chick
embryos [18,21]. In contrast, genetic studies in the mouse
has revealed that the PI3K pathway is not required as
knock-out of PDK1, an upstream activator of PI3K, still
allowed expression of Dusp6 albeit in a disorganized fash-
ion [20].
Analysis of the RAS/MAPK pathway under similar experi-
mental conditions indicates that this pathway is also
important for Dusp6 gene expression. For instance, the
implantation of beads soaked with PD184352, a specific
inhibitor of Mek can also block Dusp6 expression in the
chick limb bud and somites, implicating the RAS/MAPK
pathway in regulating Dusp6 expression [16,20,22]. Fur-
ther, over-expression of Dusp6 itself, which would result
in the removal of activated ERKs and hence the shutdown
the RAS/MAPK pathway, resulted in the down regulation
of  Dusp6  transcription [11,20]. Although these studies
highlight the complex nature of Dusp6 gene regulation
downstream of the FGF receptor it is however clear that
Dusp6 is a direct target of FGF signalling. This concept is
supported by the fact that the presence of Erk phosphor-
ylation correlates with Dusp6 expression throughout chick
embryogenesis [12]. A detailed map of ERK activation was
described and Dusp6 expression was found to colocalize
with activated ERKs in all tissues throughout chick devel-
opment [12]. Thus FGF activity can be directly measured
by either the presence of phosphorylated ERKs or indi-
rectly by the presence of Dusp6 transcripts.
The generation of transgenic lines that express fluorescent
reporters in response to FGFs would allow live visualiza-
tion of FGF activity during development. Since zebrafish
embryos develop ex utero, the direct visualization of
d2EGFP in the embryos can provide an indirect biosensor
for FGF activity in vivo. In this report we have generated
transgenic zebrafish lines that expresses a destabilizedBMC Developmental Biology 2007, 7:62 http://www.biomedcentral.com/1471-213X/7/62
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form of Green Fluorescent Protein (d2EGFP) under the
control of active FGF signalling. To achieve this we iso-
lated the promoter region of the dusp6 gene and fused it to
d2EGFP reporter gene. d2EGFP fluorescence can be visual-
ised in transgenic embryos within multiple tissues where
activated ERKs (phosphorylated) have been detected, and
where expression of FGF ligands, receptors and target
genes such as sef,  sprouty4, pea3 and  erm  have been
described [9,10,13,15,23-31].
The zebrafish has become a viable model organism for
chemical screens [32-34]. With the generation of fluores-
cent transgenic reporter zebrafish lines it is possible to dis-
cover specific molecules that can alter differentiation
events during organogenesis [35]. We have validated the
FGF reporter lines as tools to identify novel FGF modula-
tors and in counter screens it is possible to determine
compound specificity towards two closely related RTK
pathways. The generation of in vivo reporters for FGF activ-
ity will provide a valuable tool to screen for genes or
chemicals that modulate FGF signalling.
Results
Generation of transgenic FGF reporter lines
The zebrafish Dusp6  gene locus was identified by PCR
screening a BAC library from Genome Systems. The BAC
clone contained the full gene Dusp6 locus, and a 10 Kb
fragment that includes the 5' untranslated sequence
within exon I was subcloned into a vector containing the
d2EGFP, a gene that encodes a destabilised green fluores-
cent protein that has a two hour half-life (Figure 1A) [36].
Since FGF signalling during embryogenesis is dynamic, we
reasoned that a destabilized form of EGFP would likely
recapitulate the endogenous expression of dusp6 mRNA.
1-cell stage zebrafish embryos were co-injected with the
transgenic DNA construct and I-Sce 1 meganuclease as
described by Thermes et al. to generate transgenic lines
[37]. Injected embryos were raised to adulthood and
screened for potential germline carriers by d2EGFP expres-
sion. Ten founder transgenic animals were identified in
the F1 generation. While d2EGFP expression levels dif-
fered between each of the transgenic lines, the expression
patterns were identical between the transgenic lines. We
maintained four of the strongest lines
(Tg(Dusp6:d2EGFP)pt6-pt9), and for this study we utilized
the line Tg(Dusp6:d2EGFP)pt6. We have generated
homozygous lines for several of the transgenes and
observed the expected Mendelian inheritance. Further,
there were no deleterious effects noted in transgenic ani-
mals, suggesting that insertion of the DNA construct did
not impact zebrafish growth and development.
Expression of d2EGFP is localized to FGF signalling centres 
in transgenic embryos
d2EGFP was first visualized as early as dome stage within
the prospective dorsal region of the embryo, consistent
with the restricted dorsal expression of dusp6 mRNA and
with the initial expression patterns of fgf3 and -8 (com-
pare Figure 1B to 1D) [11]. The fluorescent pattern was
supported by the expression of d2EGFP mRNA as tested by
in situ hybridisation (Figure 1C). At sphere stage, d2EGFP
expression is maintained within the dorsal region and
colocalises with dusp6 expression, a domain where the
organiser (shield) eventually forms (compare Figure 1E to
1F). At 6 hpf, the highest d2EGFP expression is detected
within the shield, and weakly throughout the margin,
which resembles the pattern of dusp6 mRNA at this stage
(compare Figure 1J to 1H).
Reporter gene expression was also analysed at later stages
by in situ hybridisation performed to detect the presence
of d2EGFP mRNA. At bud stage (10 hpf), d2EGFP tran-
Generation of Dusp6 DNA construct and expression of  d2EGFP in transgenic embryos Figure 1
Generation of Dusp6 DNA construct and expression 
of d2EGFP in transgenic embryos. (A) Diagram showing 
the Dusp6 gene locus and the DNA construct used in gener-
ating transgenic zebrafish. (B, E, & H) dusp6 expression at 
oblong (B), dome (E), and shield stage. (C) d2EGFP mRNA 
expression at sphere stage. (D, F, G, I, & J) 
Tg(Dusp6:d2EGFP)pt6 embryos at dome (D), 30% epiboly (F & 
G), and shield (I & J) stage. (B-F & I) are lateral views and 
(H & J) are animal views. Red arrowheads mark dorsal 
region of the embryo.BMC Developmental Biology 2007, 7:62 http://www.biomedcentral.com/1471-213X/7/62
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scripts can be detected within the posterior ventral
domain and within the presumptive hindbrain, where
fgf8 expression has been noted (Figure 2A) [14,30,31]. By
24 hpf, d2EGFP mRNA is detected within the MHB, pha-
ryngeal arches, otic vesicle, retina, optic stalk and dorsal
diencephalon (Figure 2B). The ligands fgf8, fgf17 and fgf3,
and FGFRs are known to be expressed within these same
domains, suggesting that mRNA  expression of this
reporter gene is under the control of FGF signalling
[14,23,25,26,30,31]. In comparison to the fluorescent
protein expression, d2EGFP transcripts can be detected in
a much wider domain and also more prominent (com-
pare Figure 2A to 2C and Figure 2B to 2I). One reason for
the discrepancy can be attributed to the threshold level
Spatial and temporal d2EGFP expression in Tg(Dusp6:d2EGFP)pt6 embryos Figure 2
Spatial and temporal d2EGFP expression in Tg(Dusp6:d2EGFP)pt6 embryos. (A & B) Lateral views of d2EGFP mRNA 
expression at Bud stage and 24 hpf. (C-P) d2EGFP expression in Tg(Dusp6:d2EGFP)pt6 embryos, stages are indicated in each 
panel. At bud stage (C & D), d2EGFP is detected in the hindbrain (r3/r4, yellow arrowhead) and within the caudal region in 
the DFCs. (E, G & K) From 8- to 14-somite stages, lateral views show expression of d2EGFP in cells lining Kupffer's vesicle, 
within r4 (r4, yellow arrowhead) and the mid-hindbrain boundary (mhb, red arrowhead). (F & H) Dorsal views show high 
d2EGFP expression within the MHB, r4 and the anterior lateral plate mesoderm (alpm, red brackets). (H) At 10-somite stage 
initial d2EGFP expression is detected within the trigeminal ganglia (tg, blue arrow). (I & J) 24 hpf embryo showing d2EGFP 
expression in the MHB, trigeminal ganglia, dorsal retina (rt, white arrow) and pharyngeal endoderm (pe, yellow bracket). (K & 
L) 14 and 20-somite stage embryo highlighting the expression of d2EGFP in Kupffer's vesicle. Higher magnifications are show in 
(K' & L'). (M) Trunk region shows d2EGFP expression within the dorsal spinal cord neurons (spn, white arrow) at 24 hpf. 
(N) At 50 hpf expression is noted in the MHB, trigeminal ganglia, pharyngeal endoderm and otic vesicle (ot, blue bracket). (O) 
Ventral view of 50 hpf, showing d2EGFP expression in the jaw (white bracket). (P) At 56 hpf, strong expression in noted in the 
trigeminal ganglia, the jaw and also in neurons within the dorsal diencephalon.BMC Developmental Biology 2007, 7:62 http://www.biomedcentral.com/1471-213X/7/62
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required for visualisation of d2EGFP protein as compared
to the detection of transcripts by in situ hybridisation.
At bud stage, fluorescent protein can be visualized within
the medial neural plate, presumptive hindbrain and at a
position that corresponds to the site where the Dorsal
Forerunner Cells (DFCs) in the posterior domain of trans-
genic embryos have been described (Figure 2C &2D)
[38,39]. The DFCs represent a specialized group of non-
involuting cells that migrate just ahead of the shield dur-
ing gastrulation and eventually forms a fluid filled struc-
ture known as Kupffer's vesicle, a transient organ
particular to teleosts [38,39]. Kupffer's vesicle is thought
to serve equivalent functions in establishing left-right
polarity as the mouse node [40-43].
By the 6-somite stage, strong d2EGFP fluorescence can be
detected in the MHB, the hindbrain with strongest expres-
sion in r4, the anterior lateral plate mesoderm and the
Kupffer's vesicle (Figure 2E &2F). Approximately two
hours later at the 10-somite stage expression of d2EGFP is
located within the same domains as described for the 6-
somite stage with the addition of the trigeminal ganglia
(Figure 2G &2H). The expression within Kupffer's vesicle
is quite striking as the structure is completely outlined by
d2EGFP positive cells from the 6-somite onwards (Figure
2C, 2E, 2G, 2K and 2K'). In the zebrafish, a role for FGF
signalling has been suggested in the formation of
Kupffer's vesicle, as fgf8 is expressed in the DFCs at gastru-
lation, and this structure is absent in about 30% of
ace(fgf8) mutants [44]. The Tg(Dusp6:d2EGFP)pt6 line con-
firms that the DFCs and Kupffer's vesicle receive FGF sig-
nals from the time when the DFCs begin to coalesce and
right through to the 20-somite stage when Kupffer's vesi-
cle begins to collapse (Figure 2K, 2L, 2K', &2L'). Time
lapse imaging of the transgenic embryos shows fluores-
cent DFCs migration towards the posterior region of the
embryo and the formation of Kupffer's Vesicle at the 6-
somite stage [see Additional files 1, 2, 3 and 4]. d2EGFP
expression is still noted throughout these stages and even
after the collapse of Kupffer's vescles when these epithelial
cells migrate towards the tail bud and contribute to meso-
dermal tissues such as notochord, posterior somites and
the tail bud (see Additional files 2, 3 and 4) [38,39]. By
the 26-somite stage, the Kupffer's vesicle cells have lost
their expression of d2EGFP, suggesting that these cells no
longer receive FGF signals (data not shown).
At 24 hpf, d2EGFP can be visualized within the dorsal ret-
ina, trigeminal ganglia, otic vesicles, within the dorsal
diencephalon, and dorsal spinal cord neurons (Figure 2I,
2J &2M). These domains of d2EGFP expression are con-
sistent with expression of FGF ligands, receptors and
known target genes such as erm, pea3, sef and sprouty4,
suggesting that the transgenic line reports on FGF activity
in vivo [13,15,24,27-29]. d2EGFP expression persists
throughout the next day of development in a majority of
the same domains as at 24 hpf and continues up to 56 hpf
(Figure 2N, 2O &2P). The one exception is that dorsal ret-
ina expression is lost, while lens expression becomes
stronger from 36 hpf onwards (Figure 2N). Expression at
later stages can also be detected within the developing jaw
and further refined within the pharyngeal arches and the
pectoral fins (Figure 2N &2O, pectoral fins not shown). A
dorsal view of a 56 hpf transgenic embryo reveals d2EGFP
expression within distinct cells in the dorsal dien-
cephalon, suggesting that these particular cells are
responding to FGF signals (Figure 2P). Of particular inter-
est is that there seems to be an asymmetric distribution of
fluorescent cells with respect to the left-right axis, imply-
ing that within this region of the diencephalon, FGF sig-
nalling is asymmetrical (Figure 2P). An alternative view is
that the asymmetric expression of d2EGFP is a result of
anatomical or stochastic (random) differences between
the left and right side of the diencephalon. Studies have
shown that the left habenular nuclei is larger and the par-
apineal gland is situated to the left of the midline, suggest-
ing that d2EGFP expression reflects structural difference
between the left and right dorsal diencephalon [45,46].
The domains of d2EGFP expression in the transgenic
embryos were consistent with many of the regions where
endogenous dusp6 transcripts have been detected. How-
ever, dusp6 mRNA expression was not fully recapitulated
in the transgenic embryos, in particular FGF activity and
dusp6 expression have been well documented within the
somites and tail bud and yet no expression of d2EGFP
mRNA or protein were detected in these regions (Figure 2)
[11]. One explanation is that only 10 Kb of upstream
Dusp6 promoter sequence was used to generate the DNA
construct for transgenesis, hence it is likely that somitic
and tail bud enhancers were not present within this
sequence.
In summary we have generated several transgenic lines
that express d2EGFP under the control of the Dusp6 pro-
moter, a gene that is directly regulated by FGF signalling
during development. Since d2EGFP has a half life of just
two hours, it is likely that domains of high d2EGFP
expression represents cells that respond to active FGF sig-
nalling as opposed to cells inheriting fluorescent protein
from their ancestors.
FGF signalling controls reporter gene expression
To test whether d2EGFP expression is responsive to exper-
imental modulation in FGF signalling, we injected fgf8
mRNA (10 pg) into 2–4 cell stage Tg(Dusp6:d2EGFP)pt6
embryos. As expected, expression of d2EGFP was greatly
expanded in fgf8-injected embryos at the gastrula stage
(compare Figure 3B to 3A). Conversely, injection of fgf8-BMC Developmental Biology 2007, 7:62 http://www.biomedcentral.com/1471-213X/7/62
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MOs (10 ng) resulted in a suppression of d2EGFP expres-
sion within the MHB and retina, while d2EGFP expression
within the trigeminal ganglia was unaffected (compare
Figure 3D to 3C). To confirm these findings we analyzed
d2EGFP expression in two mutant zebrafish lines that
exhibit defective FGF signalling [31,47]. We in-crossed
Tg(Dusp6:d2EGFP)pt6  into the ace(fgf8)  mutant and
expression of d2EGFP within the MHB was greatly dimin-
ished in mutant embryos from 20 hpf onwards (not
shown). This is clearly evident at 28 hpf when the MHB is
morphologically distinguishable between wildtype sib-
lings and mutants (Figure 4A–D). Furthermore expression
within the retina and lens was absent, while expression in
the optic stalk and trigeminal ganglia were unaffected at
28 hpf (Figure 4A–D). In the noi(pax2.1) mutant, d2EGFP
expression was markedly reduced in the MHB, where FGF
signalling is absent, however expression within the retina,
lens, trigeminal ganglia and otic vesicles was unaltered. In
contrast to the ace mutants, expression of d2EGFP within
the optic stalk is severely reduced as this structure fails to
from in the noi mutants (compare Figure 4E to 4F) Taken
D2EGFP expression in fgf8/ace and pax21/noi mutants Figure 4
D2EGFP expression in fgf8/ace and pax2.1/noi 
mutants. (A-F) Lateral views of Tg(dusp6:d2EGFP)pt6 
embryos at 28 hpf crossed into ace or noi mutants. Genotype 
is listed in bottom left corner. (A & B) Brightfield images of 
wildtype sibling and ace mutant embryo, respectively. (C & 
D) d2EGFP expression in WT sibling and ace mutant. Note 
loss of d2EGFP expression within the MHB, dorsal retina, 
and the smaller otic vesicle, while d2EGFP expression in the 
trigeminal ganglia is unaffected. (G & H) Brightfield images of 
wildtype sibling and noi mutant embryo. (E & F) d2EGFP 
expression is lost in the MHB and optic stalk. In contrast to 
the ace mutants, expression within the dorsal retina and otic 
vesicles are normal.
D2EGFP expression is dependant on FGF signaling Figure 3
D2EGFP expression is dependant on FGF signaling. 
(A & B) Lateral views of gastrula staged Tg(Dusp6:d2EGFP)pt6 
embryos. Control uninjected is shown in (A), while in (B) 
fgf8 mRNA injected at the 2-cell stage. Expression of d2EGFP 
is greatly expanded in fgf8-injected embryos. (C & D) Lat-
eral views of 28 hpf transgenic embryos. (C) Control MO 
injected (D) fgf8-MO injected embryo shows loss of d2EGFP 
expression within the MHB, dorsal retina and smaller otic 
vesicles. Red arrowhead: MHB; yellow arrow: dorsal retinal; 
blue arrowhead: optic stalk; red bracket: otic vesicle.BMC Developmental Biology 2007, 7:62 http://www.biomedcentral.com/1471-213X/7/62
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together, these results show that we have generated a
transgenic reporter line that expresses d2EGFP under the
control of FGF signalling during development.
Treatment of Tg(Dusp6:d2EGFP)pt6 embryos with known 
FGF pathway inhibitors
Given that Tg(Dusp6:d2EGFP)pt6  embryos respond to
changes in FGF signalling, these embryos can provide a
valuable tool to screen for molecules that modulate FGF
signalling in vivo. To validate that these reporter lines can
measure changes in FGF activity in a chemical screen,
Tg(Dusp6:d2EGFP)pt6 embryos were treated with known
inhibitors of the FGF pathway. For our studies we selected
transgenic embryos at 24 hpf and treated with com-
pounds for 8 hours. We reasoned that since the half-life of
d2EGFP is 2 hours, then an inhibitor of FGF signalling
should substantially reduce d2EGFP fluorescence after 6–
8 hours of treatment. Furthermore, since embryos at this
developmental stage (24 hpf) have already formed many
of the structures that express d2EGFP such as the MHB,
trigeminal ganglia and otic vesicles, then the assay would
directly measure loss of d2EGFP fluorescence as a conse-
quence of FGF inhibition and not per se a loss of these tis-
sues.
We treated transgenic embryos with the indolinone FGF
receptor inhibitor, SU5402 [Additional file 5 shows the
structure of the compounds used in this study] [48].
SU5402 has been extensively used to block FGF signalling
in zebrafish and Xenopus laevis embryos with doses rang-
ing from 20 μM to 160 μM [10,27,49,50]. In this study, 1
μM SU5402 was effective at suppressing expression of
d2EGFP within the trigeminal ganglia and reducing MHB
fluorescence after only 8 hours of treatment (compare Fig-
ure 5A to 5B). At 5 μM of SU5402, expression of d2EGFP
was markedly reduced within the MHB, and even elimi-
nated within the dorsal retina and trigeminal ganglia (Fig-
ure 5C). At 10 μM, d2EGFP fluorescence in the transgenic
embryos was completely abolished (Figure 5D).
Treatment with other receptor tyrosine kinase inhibitors
was also performed to determine the specificity of this
assay for identifying other small molecules that can mod-
ulate FGF signalling. We assessed the activity of several
Vascular Endothelial Growth Factor Receptor (VEGFR)
and Platelet Derived Growth Factor Receptor (PDGFR)
inhibitors to reveal if these compounds, structurally
related to SU5402, could suppress d2EGFP expression in
the FGF reporter lines. We reasoned that most of these
compounds contain the same indolinone backbone as
SU5402, and therefore some would also block FGFR sig-
nalling in the zebrafish. Thus the analysis of these com-
pounds in the FGF reporter line can determine the
chemical structures that suppress FGF signalling from a
family of related molecules. One of the first indolinones
to undergo clinical trials was SU5416, a reported specific
inhibitor for VEGFR2 [see Additional file 5] [51-53].
SU5416 was added to 24 hpf stage transgenic embryos for
6 hours to determine if this compound is specific for
VEGFR versus FGFR. While this compound exhibits
autofluorescence, especially within the yolk, the expres-
sion of d2EGFP did not markedly change at 1 μM (Figure
5E). In contrast at 5 μM, the trigeminal ganglia and MHB
fluorescence was markedly diminished (Figure 5F). At
even higher doses, SU5416 completely eliminated
Validation of Tg(Dusp6:d2EGFP)pt6 line for chemical screening Figure 5
Validation of Tg(Dusp6:d2EGFP)pt6 line for chemical 
screening. (A-Y) Lateral views of 30 hpf embryos treated 
with the compound and dose are indicated on the bottom 
right. The protein targets for these compounds are listed in 
the top right hand corner. (A) Embryo incubated in 0.5% 
DMSO as control. (B-D) Increasing doses of SU5402 sup-
pressed d2EGFP expression in the MHB (red bracket), 
trigeminal ganglia (red arrow) and dorsal retina (red arrow-
head). (E-H) Increasing doses of SU5416, a non-specific 
inhibitor of VEGFRs, suppressed FGF signalling. (I & J) Oxin-
dole I another related VEGFR inhibitor also suppressed 
d2EGFP fluorescence in transgenic embryos. (K-N) In con-
trast, two compounds with similar chemical structure 
SU4312 and SU11652, did not block FGF signalling. (O & P) 
Likewise, two unrelated inhibitors of PDGFR and VEGFR, 
SU1433 and SU1498 also failed to suppress d2EGFP expres-
sion. (Q-T) PP2 and SU6656, two Src Kinase inhibitors sup-
pressed FGF signalling in transgenic embryos.BMC Developmental Biology 2007, 7:62 http://www.biomedcentral.com/1471-213X/7/62
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d2EGFP expression within the transgenic embryos, even
though the treated embryos exhibited strong fluorescent
yolks, the expression of d2EGFP within the MHB was
clearly eliminated (Figure 5G &5H). These results suggest
that SU5416 is not completely specific to VEGFR2 at these
concentrations and it can block FGF signalling. Similarly,
Oxindole I was also effective at blocking d2EGFP expres-
sion, however a much higher dose (40 μM) was required
[see Additional file 5], and (Figure 5I &5J). SU4312 repre-
sents another indolinone inhibitor of VEGFR, which has
been shown to block autophosphorylation of VEGFRs
[54]. In contrast to SU5416, treatment up to 40 μM of
SU4312 had little effect in the expression of d2EGFP
within the MHB and trigeminal ganglia in the
Tg(Dusp6:d2EGFP)pt6 embryos [see Additional file 5] and
(Figure 5K &5L). A newer generation of indolinone com-
pound was also tested to determine its specificity towards
VEGFR/PDGFR versus FGFR. SU11652, has been shown
to have at least 100-fold greater inhibitory effect targeting
a VEGFR and PDGFR versus FGFR [see Additional file 5]
[55,56]. In our assays, SU11652 did not alter d2EGFP
expression suggesting that this compound does not block
FGF signalling (Figure 5M &5N). We also treated trans-
genic embryos with two structurally unrelated VEGF sig-
nalling inhibitors, SU1498 and SU1433 (also known as
AG1433) to determine the specificity of these molecules
[see Additional file 5] [57-59]. Both compounds have
been shown to be effective at blocking VEGFR, and to a
lesser extent basic FGF in HUVEC tubulogenesis assays
[58]. Treatment with high doses of SU1433 or SU1498
did not alter d2EGFP fluorescence in the transgenic
embryos, suggesting that these chemically divergent com-
pounds do not block FGF signalling in the zebrafish at the
doses indicated (Figure 5O &5P).
We next determined the activity of Src Kinase inhibitors
and their role in FGF signalling in the early embryo as pre-
vious reports have shown that several Src family members
function to relay FGF signalling [60,61]. PP2, an inhibitor
of several Src Kinases including Fyn and Lck as well as
PDGFRs and Bcr-Abl, only mildly altered d2EGFP expres-
sion at 20 μM (Figure 5Q), a dose that is several fold
higher than what has been shown to inhibit Fyn and Lck
in cell culture [62,63]. SU6656, a more specific inhibitor
of Src kinases, exhibited robust inhibitory activity in these
assays. At concentrations of 1 μM, expression of d2EGFP
was completely abolished within the MHB, trigeminal
ganglia and the retina. The concentration of SU6656 was
within the range that is known to be specific for blocking
mouse Src kinase activity and not other related tyrosine
kinases (Figure 5R–T) [63]. In fact 1 μM SU6656 is likely
to inhibit only the Src members, Yes, Fyn, Src and Lyn,
with Yes kinase exhibiting higher sensitivity, suggesting
that Yes is required for FGF signalling in the zebrafish
embryo [63].
The results from these experiments support the use of
transgenic FGF reporter lines to screen for small molecules
that affect FGF signalling. Given the rapid nature of these
screens as d2EGFP expression can be suppressed in just 6
hours, it is likely that a chemical screen would identify
compounds that directly modulate FGF signalling.
Suppression of dusp6 expression in embryos treated with 
FGF inhibitors
To confirm that suppression of d2EGFP fluorescence
reflects reduced FGF target gene transcription, we ana-
lyzed  dusp6  mRNA expression in wildtype embryos
treated with chemical inhibitors (Figure 6). As predicted,
compounds that suppressed fluorescence in
Tg(Dusp6:d2EGFP)pt6embryos also resulted in a reduction
of dusp6 transcripts (Figure 6B to 6F). SU5402, SU6656,
SU5416 and Oxindole I all suppressed dusp6 expression
after 10hr treatment at the dose indicated. In particular,
dusp6 expression within the dorsal diencephalon, pharyn-
geal endoderm and optic stalks were greatly reduced in
embryos treated with SU5402, S6656, SU5416 and Oxin-
dole I (Figure 6B–6F). However, dusp6 expression in the
MHB was either completely eliminated by SU5402 or
only mildly affected by the other compounds in treated
embryos (Figure 6B–6F). These results suggest that the
MHB represents a region of highest levels of FGF activity
in the embryo during these developmental stages. Finally,
compounds that did not alter overall d2EGFP fluores-
cence (SU11652 and SU4312) in treated FGF reporter line
also did not exhibit changes in dusp6 transcript levels (Fig-
ure 6G &6H).
Expression of dusp6 in chemically treated embryos Figure 6
Expression of dusp6 in chemically treated embryos. 
(A-H) Lateral views of 24 hpf embryos treated with com-
pounds indicated on bottom left and probed for the presence 
of dusp6 transcripts. (A) DMSO control, dusp6 is strongly 
expressed in the MHB (brackets), pharyngeal endoderm 
(arrow). (B) SU5402 at 10 μM greatly suppresses dusp6 
transcription, while at a higher dose, 20 μM (C) dusp6 
expression is almost eliminated. (D-F) SU6656, SU5416 and 
Oxindole I treated embryos exhibited weaker dusp6 expres-
sion. (G & H) SU4312 and SU11652 did not significantly 
alter dusp6 expression.BMC Developmental Biology 2007, 7:62 http://www.biomedcentral.com/1471-213X/7/62
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Specificity of small molecule FGF signalling inhibitors can 
be evaluated with Tg(Fli:EGFP)y1 transgenic embryos
Since the results obtained with the VEGFR inhibitors,
SU11652, SU1433 and SU4312, were predominantly neg-
ative and did not alter d2EGFP expression in the FGF
reporter embryos, we wanted to confirm that these com-
pounds were permeable in the embryo and have an effect
on zebrafish VEGR signalling. One approach is to test the
activity of these compounds in a zebrafish angiogenesis
assay. Such assays have been developed to screen for novel
antiangiogenic compounds that can block the formation
of the zebrafish intersegmental vessels (ISV), and trans-
genic lines that delineate the ISV have been used for such
assays [35,64]. For our studies we analysed ISV outgrowth
in the Tg(Fli1:EGFP)y1 line that expresses eGFP under the
control of the Fli1 promoter [65]. To determine the effects
of these VEGFR inhibitors on ISV outgrowth, we treated
Tg(Fli1:EGFP)y1transgenic embryos at 24 hpf for 8 hours.
Treatment within this limited temporal window would
reveal whether a compound could specifically block
VEGFR signalling and ISV outgrowth as somites, dorsal
aorta and posterior cardinal vein would have already been
established at 24 hpf. Furthermore previous studies have
highlighted the requirement for active VEGFR signalling
that is relayed through PLCγ and AKT to form the ISV
using a similar time frame [64-66].
We first treated Tg(Fli1:EGFP)y1 embryos with SU1433,
SU11652 and SU4312, compounds that did not alter flu-
orescence in the FGF reporter embryos, to determine if
these compounds can block VEGFR signalling in the
zebrafish. As predicted, all three compounds suppressed
ISV outgrowth in the transgenic embryos, thus exhibiting
specificity towards VEGFRs, and confirming that these
compounds are permeable in the embryo (Figure 7B–D).
Similar effects on ISV outgrowth were noted with Oxin-
dole I, a compound that blocked FGF signalling, however
at a much lower dose (5 μM) that was required to block
fluorescence in Tg(Dusp6:d2EGFP)pt6 embryos (Figure 7E).
This result suggests that Oxindole I has a higher activity
towards VEGFR signalling. We next assayed the effects of
the FGF receptor inhibitor, SU5402, on ISV outgrowth.
SU5402 treated Tg(Fli1:EGFP)y1 embryos also resulted in
the suppression of ISV formation (Figure 7F). The original
description of SU5402 had provided evidence that this
compound would interact with the ATP binding domain
Expression of fli1 in intersegmental vessels in indolinone  treated embryos Figure 8
Expression of fli1 in intersegmental vessels in 
indolinone treated embryos. (A-H) Lateral trunk views 
of fli mRNA expression within the ISV. (A) DMSO control 
shows vessel sprouts at 28 hpf. (B-G) Embryos treated with 
the compounds indicated show loss of ISV sprouts, while in 
(H) SU6656 did not affect these vessels.
Specificity of Indolinones towards FGFR versus VEGFR sig- nalling Figure 7
Specificity of Indolinones towards FGFR versus 
VEGFR signalling. (A-H) Lateral trunk views of 32 hpf 
Tg(Fli1:EGFP)y1 embryos treated with the chemicals shown on 
the bottom left. (A) DMSO control shows embryo with nor-
mal expression of EGFP within the intersegmental vessels. 
(B) 20 μM SU1433, (C) SU11652, (D) SU4312 (E) Oxin-
dole I, (F) SU5402, and (G) SU5416 all suppressed ISV out-
growth as indicated by red arrows. (H) SU6656 in contrast 
did not alter ISV formation.BMC Developmental Biology 2007, 7:62 http://www.biomedcentral.com/1471-213X/7/62
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of the VEGFR and was supported by unpublished data
that SU5402 did block VEGFR signalling in tissue culture
experiments, yet SU5402 is often used as a specific FGFR
inhibitor. Thus we stress that the effects of SU5402 treat-
ment may not exclusively reflect a blockade of FGFRs.
SU4312 and SU5416, two compounds that have previ-
ously been shown to inhibit VEGF signalling also inhib-
ited ISV outgrowth (Figure 7F &7G) [51,54,67]. Thus
SU5416 strongly suppressed both VEGF and FGF signal-
ling in our assays, while SU4312 was specific for VEGF sig-
nalling. In contrast, treatment of Tg(Fli:EGFP)y1 embryos
with the inhibitor of Src kinases, SU6656, did not block
ISV outgrowth, suggesting that VEGF signalling does not
require Src kinases to direct vessel formation (Figure 7H).
To confirm our findings that VEGFR inhibitors did indeed
block intersegmental vessel outgrowth, we performed in
situ hybridisation studies to detect the presence of these
vessels through fli1  expression. Treatment of embryos
with 1 μM Oxindole 1, 10 μM SU5416, 20 μM SU4312, 1
μM SU5402, or with 20 μM SU11652 prevented ISV for-
mation as determined by loss of fli1 expression in the
intersegmental sprouts (Figure 8B–G). Again these results
confirm that SU5402 can block VEGFR signalling in the
zebrafish and is not a specific inhibitor of FGFRs. In con-
trast, expression of fli1 within the ISV was unaffected in
embryos treated with 10 μM SU6656, confirming the
notion that Src kinases are not required in ISV outgrowth
(Figure 8H).
Discussion
In this paper we present the generation of a zebrafish
transgenic line that reports on FGF signalling during
embryonic development. Expression of d2EGFP in these
embryos is regulated by FGF signalling and maps to
domains where activated ERKs have been detected [7-12].
Time-lapse imaging of transgenic embryos shows the
dynamic expression of d2EGFP throughout embryogene-
sis. These movies demarcate the formation of Kupffer's
vesicle, as d2EGFP labels the DFCs from gastrulation
onwards. Since Kupffer's vesicle plays a critical role in the
determination of left-right polarity these lines will pro-
vide a valuable tool to access the integrity of Kupffer's ves-
icle formation in left-right polarity mutants [41,42].
Furthermore, these lines provides a way to identify DFCs
in post-gastrulation but pre-Kupffer's vesicle stages in live
embryos. To our knowledge this is the only line that spe-
cifically labels the DFCs with fluorescence as they migrate
during gastrulation to eventually form Kupffer's vesicle.
This is in contrast to the Tg(twhh:GFP)  line that also
expresses GFP in Kupffer's vesicle, as GFP expression was
only detected once the vesicle had formed at the 6-somite
stage [68].
While a majority of the d2EGFP expression resembles that
of dusp6 mRNA during development, a notable exception
is the lack of d2EGFP expression within the developing
somites and tail bud, two domains where FGFs and Erk
activation have been described [3,12,31]. Since only 10
Kb of upstream promoter sequence was used in generating
the reporter construct, it is likely that the somitic and tail
bud enhancers elements are not part of this sequence.
The expression of d2EGFP is under the control of FGF sig-
nalling as manipulation of FGF activity in transgenic
embryos resulted in altered d2EGFP expression. These
lines will provide useful tools to analyze the integrity of
FGF signalling under experimental conditions such as
antisense MOs injections or in mutant strains. Previously,
Balciunas  et al. described a transposon-mediated
enhancer trapped line that contains an EGFP reporter
inserted 30 Kb within the Dusp6 locus (ET7 line) [69]. In
the ET7 transgenic embryos, EGFP is detected within the
MHB, pharyngeal endoderm and somites at 24 hpf, sug-
gesting that Dusp6 enhancers may regulate the expression
of eGFP [69]. However, it has not been demonstrated if
EGFP expression in the ET7 embryos can respond to
experimental changes in FGF signalling [69]. We believe
that Tg(Dusp6:d2EGFP)pt6 represent the first description of
vertebrate transgenic embryos that can report on FGF
activity in vivo.
We have used these transgenic lines to validate an
approach to screen for small molecules that can modulate
FGF signalling. Our results show that within 6 hours of
treatment with the FGFR inhibitor, SU5402, complete
suppression of de2GFP expression ensued, confirming
that these lines can rapidly identify compounds that mod-
ulate FGF signal transduction in the embryo. Since FGFRs
are members of a larger family of receptor tyrosine kinases
we wanted to determine if compounds that are structur-
ally related to SU5402 could also block FGF signalling in
the embryo. We determined the specificity of several
VEGFR and PDGFR inhibitors that contain the same
indolinone backbone as SU5402. From our studies it was
clear that SU5416 and Oxindole I, two inhibitors of
VEGFR could block d2EGFP expression in the FGF
reporter embryos. Furthermore, from these studies we
also revealed a putative role for Src kinases in relaying FGF
signals in the zebrafish as treatment with Src kinase inhib-
itors, PP2 and SU6656, suppressed d2EGFP fluorescence.
Since several members of this kinase family are expressed
early and within cells that receive FGF signals in the devel-
oping embryo, including Yes and Fyn, the preferred tar-
gets of SU6656, it is reasonable to think that these Kinases
are involved in FGF signalling [70-72].
We have coupled the pilot screen with the Tg(Fli1:EGFP)y1
transgenic line to assay the specificity of these compoundsBMC Developmental Biology 2007, 7:62 http://www.biomedcentral.com/1471-213X/7/62
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between FGFR and VEGFR signalling. We confirm that
SU5416, SU4312, SU11652, Oxindole I and surprisingly
SU5402 exhibited inhibitory effects on ISV outgrowth and
probably a result of VEGFR inhibition. In the original
study, a crystal structure of SU5402 complexed with the
FGFR1 kinase domain highlighted the exact peptide resi-
dues that interfaced with the compound [48]. Since these
residues are also highly conserved with the VEGFRs kinase
domain, it was postulated that SU5402 could interact
with the VEGFRs [48]. Furthermore the authors refer to
unpublished observations that SU5402 did inhibit
VEGFR signalling in living cells [48]. Our studies reveal
that SU5402 can block ISV outgrowth, which we interpret
as a result of VEGFR inhibition in the zebrafish embryo.
Alternatively, our data could imply that FGFRs are
required for ISV outgrowths given that FGFs are known to
play a role in angiogenesis [53]. However from the pub-
lished literature, FGFR1-4 are not expressed in the ISV to
support the role for this pathway in vasculogenesis
[25,26]. SU5402 has been used extensively as a FGFR
inhibitor in many studies. In light of these findings, other
experiments should be considered to test whether SU5402
might also block VEGFR signalling to elicit the observed
phenotypes.
Conclusion
This study describes the generation of transgenic
zebrafish, Tg(Dusp6:d2EGFP)pt6, that reports on FGF activ-
ity during development. The expression of d2EGFP mir-
rors the expression of several FGF ligands in the early
embryo and will provide a tool to analyse FGF signalling
under various experimental conditions. We have per-
formed a pilot screen to validate these lines in chemical
screens to identify novel compounds that can modulate
FGF activity. This rapid screening protocol can be coupled
with the Tg(Fli1:EGFP)y1 line to eliminate compounds
that can potentially cross react with the VEGFR pathway.
Finally, acridine orange staining will further eliminate
toxic compounds, thus by following these procedures it is
possible to identify chemicals that specifically modulate
FGF signalling in vivo.
Methods
Generation of Tg(Dusp6:d2EGFP) zebrafish
A Dusp6 BAC clone was identified by PCR from BAC DNA
pools as directed by manufacturers protocols (Genome
Systems). A 10 Kb Kpn1 fragment was identified that con-
tain parts of Exon 1 (441 bp) and approximately 9.5 Kb of
upstream promoter sequence (see Figure 1A). This Kpn1
fragment was subcloned into the Kpn1 site of
pSce1d2EGFP vector (pSce1 vector with d2EGFP cDNA
cloned into the multiple cloning site). 20 pg of
pDusp6:d2EGFP plasmid DNA was injected into the 1-cell
embryo with I-Sce 1 (New England Biolabs, Ipswich, MA)
restriction enzyme as described in [37]. These Founder F0
injected embryos were raised to adulthood and incrossed
to identify transgenic founders. We identified 10 founder
lines that expressed d2EGFP within regions of known FGF
activity in the developing embryo. Four lines exhibited
strong expression throughout development and were
maintained.  Tg(Dusp6:d2EGFP)pt6  was used predomi-
nantly in this study.
Zebrafish Microinjection of RNA and antisense 
Morpholinos
10 pg fgf8 mRNA, 20 ng control-MO(5'-CCTCTTACCT-
CAGTTACAATTTATA-3'), and 10 ng fgf8-MO  (5'-
GAGTCTCATGTTTATAGCCTCAGTA-3') was injected into
the 2-cell stage transgenic embryos as described by Tsang
et. al and Araki et. al, respectively [13,73]. Morpholinos
were obtained from Gene-tools inc. (Philomath, OR).
Embryos were incubated for the desired stage before visu-
alisation under a Leica stereomicroscope and photo-
graphed by a Retiga Exi camera (Qimaging, Burnaby, BC
Canada). Images were analyzed in Photoshop CS (Adobe,
San Jose, CA).
In situ hybridisation
Zebrafish embryos were fixed in 4% paraformaldehyde
and whole mount in situ hybridisation was preformed
with  d2EGFP,  dusp6  and  fli1  RNA probes [11]. In Situ
methodology as described in Kudoh et. al. [14].
Chemical treatment of transgenic embryos
Five Tg(Dusp6:d2EGFP)pt6 embryos at 24 hpf were arrayed
into individual wells in a 96-well plate. 100 μl of E3, 0.5%
DMSO solution was added along with compound at the
dose indicated. SU5402 was kindly provided by Pfizer.
SU1498, SU11652, AG1433 (SU1433), SU6656, Oxin-
dole I, were all obtained from Calbiochem (EMD bio-
sciences, Inc. San Diego, CA) and SU5416, SU4312 from
Sigma-Aldrich (St. Louis, MO). Embryos were analyzed at
6–8 hour post treatment after manual dechorinonation
and treatment with tricaine to immobilise for photogra-
phy. Treated embryos were photographed under the same
settings for exposure, gain and magnification for each pic-
ture using a MZFLIII (leica) microscrope and fluorescent
illumination for GFP using endow cube (Chroma Tech-
nology Corp., Rockingham, VT). Qimaging software and
the Retiga Exi camera (Qimaging, Burnaby, BC Canada)
was used to capture the images. Each experiment was
repeated three times to show reproducibility of the assay
and at least 4 of the 5 treated embryos exhibited the same
phenotype. For treatment of Tg(Fli:EGFP)y1 embryos, five
transgenic embryos were placed into 96-well plates at 24
hpf and incubated with compound until 32 hpf. Treated
embryos were manually dechorionated and photo-
graphed as described for the FGF reporter assay. Images
were analyzed in Adobe Photoshop CS (San Jose, CA) and
false coloured under the same parameters.BMC Developmental Biology 2007, 7:62 http://www.biomedcentral.com/1471-213X/7/62
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Zebrafish imaging
Tg(Dusp6:d2EGFP)pt6 embryos were placed into a MatTek
glass bottom culture dish (MatTek Corp.) at gastrula stage
(6 hpf) and held in place with 1% low melting point aga-
rose. Embryos were photographed under low magnifica-
tion differential contract (DIC) microscopy and
fluorescent illumination for GFP using endow cube
(Chroma Technology Corp., Rockingham, VT) at 5 min
intervals until 24 hpf. Images were analyzed and proc-
essed into movies with Metamorph imaging software
(Molecular Devices, Dowlingtown PA).
Authors' contributions
The experiments described in this paper were planned,
conducted and analyzed by GAM, SCW and MT as a joint
effort. MT isolated the Dusp6  promoter, generated the
transgenic lines, described the expression of d2EGFP, and
performed experiments to determine that these lines are
responsive to FGFs. MT and GAM conceived the chemical
screen test and GAM performed the experiments detailed
in the pilot chemical screen and the in situ hybridisation.
SCW was responsible for the time-lapse imaging of these
lines. MT drafted the manuscript and all authors read and
approved the final version.
Additional material
Acknowledgements
We would like to thanks Drs Tom Smithgall, Michael Rebagliati, Neil 
Hukriede, Beth Roman and Igor Dawid for insightful discussion, and critical 
reading of the manuscript. SU5402 was kindly provided by Pfizer. The I-Sce-
I meganuclease vector and the Tg(Fli1:EGFP)y1 line was provided by Dr J. 
Wittbrodt and Dr Brant Weinstein, respectively. This work is supported 
by grants from the American Heart Association (0565400U) and Pennsyl-
vania Department of Health to MT, and from the National Institutes of 
Health (1U54 RR02241-01) to SCW.
References
1. Rhinn M, Brand M: The midbrain--hindbrain boundary organ-
izer.  Curr Opin Neurobiol 2001, 11(1):34-42.
2. Martin GR: The roles of FGFs in the early development of ver-
tebrate limbs.  Genes Dev 1998, 12(11):1571-1586.
3. Furthauer M, Thisse C, Thisse B: A role for FGF-8 in the dorsov-
entral patterning of the zebrafish gastrula.  Development 1997,
124(21):4253-4264.
4. Thisse B, Thisse C: Functions and regulations of fibroblast
growth factor signaling during embryonic development.  Dev
Biol 2005, 287(2):390-402.
5. Powers CJ, McLeskey SW, Wellstein A: Fibroblast growth factors,
their receptors and signaling.  Endocr Relat Cancer 2000,
7(3):165-197.
6. Tsang M, Dawid IB: Promotion and attenuation of FGF signaling
through the Ras-MAPK pathway.  Sci STKE 2004,
2004(228):pe17.
7. Corson LB, Yamanaka Y, Lai KM, Rossant J: Spatial and temporal
patterns of ERK signaling during mouse embryogenesis.
Development 2003, 130(19):4527-4537.
8. Schohl A, Fagotto F: Beta-catenin, MAPK and Smad signaling
during early Xenopus development.  Development 2002,
129(1):37-52.
9. Sawada A, Shinya M, Jiang YJ, Kawakami A, Kuroiwa A, Takeda H: Fgf/
MAPK signalling is a crucial positional cue in somite boundary
formation.  Development 2001, 128(23):4873-4880.
10. Shinya M, Koshida S, Sawada A, Kuroiwa A, Takeda H: Fgf signalling
through MAPK cascade is required for development of the
subpallial telencephalon in zebrafish embryos.  Development
2001, 128(21):4153-4164.
11. Tsang M, Maegawa S, Kiang A, Habas R, Weinberg E, Dawid IB: A role
for MKP3 in axial patterning of the zebrafish embryo.  Develop-
ment 2004, 131(12):2769-2779.
12. Lunn JS, Fishwick KJ, Halley PA, Storey KG: A spatial and temporal
map of FGF/Erk1/2 activity and response repertoires in the
early chick embryo.  Dev Biol 2007, 302:536-552.
13. Tsang M, Friesel R, Kudoh T, Dawid IB: Identification of Sef, a
novel modulator of FGF signalling.  Nat Cell Biol 2002,
4(2):165-169.
14. Kudoh T, Tsang M, Hukriede NA, Chen X, Dedekian M, Clarke CJ,
Kiang A, Schultz S, Epstein JA, Toyama R, Dawid IB: A gene expres-
sion screen in zebrafish embryogenesis.  Genome Res 2001,
11(12):1979-1987.
Additional file 1
Movie showing d2EGFP expression in Dorsal Forerunner Cells (DFCs). 
Movie of developing Tg(Dusp6:d2EGFP)pt6 embryo from late gastrula 
stage until bud stage. The movie shows a group of fluorescent cells, the 
DFCs as they coalesce towards the caudal region of the embryo.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-7-62-S1.mov]
Additional file 2
Movie showing d2EGFP expression in the developing embryo. Time-laspe 
imaging of developing Tg(Dusp6:d2EGFP)pt6 embryo from gastrula stage 
until 24-somite stage. Movie highlights the dynamic expression of 
d2EGFP within the developing embryo. The movie of the fluorescent 
embryo was overlayed onto the DIC-imaged movie to show clearly the 
developing embryo. Note expression of d2EGFP within the developing 
hindbrain, MHB and Kupffer's vesicle.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-7-62-S2.mov]
Additional file 3
Movie showing d2EGFP expression in Kupffer's vesicle. Time-laspe imag-
ing of Tg(Dusp6:d2EGFP)pt6 embryo from gastrula stage until 24-somite 
stage. GFP movie showing the formation of Kupffer's vesicle from the 6-
somite stage right until after this structure collapses at the 20-somite stage. 
Note Kupffer's vesicle cells collapse inwards and begin to migrate towards 
the tail bud.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-7-62-S3.mov]
Additional file 4
Movie showing d2EGFP expression in Kupffer's vesicle with DIC overlay. 
This is the same movie as Supplemental Movie 3, but overlayed with the 
DIC-imaged movie to show structures of the developing embryo.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-7-62-S4.mov]
Additional file 5
Diagram of the small molecules used in this study. The majority of the 
chemicals used in the pilot screen are related in structure and contain the 
indolinone backbone as described for SU5402.
Click here for file
[http://www.biomedcentral.com/content/supplementary/1471-
213X-7-62-S5.png]BMC Developmental Biology 2007, 7:62 http://www.biomedcentral.com/1471-213X/7/62
Page 13 of 14
(page number not for citation purposes)
15. Furthauer M, Lin W, Ang SL, Thisse B, Thisse C: Sef is a feedback-
induced antagonist of Ras/MAPK-mediated FGF signalling.
Nat Cell Biol 2002, 4(2):170-174.
16. Eblaghie MC, Lunn JS, Dickinson RJ, Munsterberg AE, Sanz-Ezquerro JJ,
Farrell ER, Mathers J, Keyse SM, Storey K, Tickle C: Negative feed-
back regulation of FGF signaling levels by Pyst1/MKP3 in
chick embryos.  Curr Biol 2003, 13(12):1009-1018.
17. Kawakami Y, Rodriguez-Leon J, Koth CM, Buscher D, Itoh T, Raya A,
Ng JK, Esteban CR, Takahashi S, Henrique D, Schwarz MF, Asahara H,
Izpisua Belmonte JC: MKP3 mediates the cellular response to
FGF8 signalling in the vertebrate limb.  Nat Cell Biol 2003,
5(6):513-519.
18. Echevarria D, Martinez S, Marques S, Lucas-Teixeira V, Belo JA: Mkp3
is a negative feedback modulator of Fgf8 signaling in the
mammalian isthmic organizer.  Dev Biol 2005, 277(1):114-128.
19. Li C, Scott DA, Hatch E, Tian X, Mansour SL: Dusp6 (Mkp3) is a
negative feedback regulator of FGF-stimulated ERK signaling
during mouse development.  Development 2007, 134(1):167-176.
20. Smith TG, Karlsson M, Lunn JS, Eblaghie MC, Keenan ID, Farrell ER,
Tickle C, Storey KG, Keyse SM: Negative feedback predominates
over cross-regulation to control ERK MAPK activity in
response to FGF signalling in embryos.  FEBS Lett 2006,
580(17):4242-4245.
21. Vieira C, Martinez S: Experimental study of MAP kinase phos-
phatase-3 (Mkp3) expression in the chick neural tube in rela-
tion to Fgf8 activity.  Brain Res Brain Res Rev 2005, 49(2):158-166.
22. Smith TG, Sweetman D, Patterson M, Keyse SM, Munsterberg A:
Feedback interactions between MKP3 and ERK MAP kinase
control scleraxis expression and the specification of rib pro-
genitors in the developing chick somite.  Development 2005,
132(6):1305-1314.
23. David NB, Saint-Etienne L, Tsang M, Schilling TF, Rosa FM: Require-
ment for endoderm and FGF3 in ventral head skeleton for-
mation.  Development 2002, 129(19):4457-4468.
24. Furthauer M, Reifers F, Brand M, Thisse B, Thisse C: sprouty4 acts
in vivo as a feedback-induced antagonist of FGF signaling in
zebrafish.  Development 2001, 128(12):2175-2186.
25. Scholpp S, Groth C, Lohs C, Lardelli M, Brand M: Zebrafish fgfr1 is
a member of the fgf8 synexpression group and is required for
fgf8 signalling at the midbrain-hindbrain boundary.  Dev Genes
Evol 2004, 214(6):285-295.
26. Tonou-Fujimori N, Takahashi M, Onodera H, Kikuta H, Koshida S,
Takeda H, Yamasu K: Expression of the FGF receptor 2 gene
(fgfr2) during embryogenesis in the zebrafish Danio rerio.
Gene Expr Patterns 2002, 2(3-4):183-188.
27. Raible F, Brand M: Tight transcriptional control of the ETS
domain factors Erm and Pea3 by Fgf signaling during early
zebrafish development.  Mech Dev 2001, 107(1-2):105-117.
28. Roehl H, Nusslein-Volhard C: Zebrafish pea3 and erm are gen-
eral targets of FGF8 signaling.  Curr Biol 2001, 11(7):503-507.
29. Munchberg SR, Ober EA, Steinbeisser H: Expression of the Ets
transcription factors erm and pea3 in early zebrafish develop-
ment.  Mech Dev 1999, 88(2):233-236.
30. Reifers F, Adams J, Mason IJ, Schulte-Merker S, Brand M: Overlapping
and distinct functions provided by fgf17, a new zebrafish
member of the Fgf8/17/18 subgroup of Fgfs.  Mech Dev 2000,
99(1-2):39-49.
31. Reifers F, Bohli H, Walsh EC, Crossley PH, Stainier DY, Brand M: Fgf8
is mutated in zebrafish acerebellar (ace) mutants and is
required for maintenance of midbrain-hindbrain boundary
development and somitogenesis.  Development 1998,
125(13):2381-2395.
32. MacRae CA, Peterson RT: Zebrafish-based small molecule dis-
covery.  Chem Biol 2003, 10(10):901-908.
33. Peterson RT, Link BA, Dowling JE, Schreiber SL: Small molecule
developmental screens reveal the logic and timing of verte-
brate development.  Proc Natl Acad Sci U S A 2000,
97(24):12965-12969.
34. Zon LI, Peterson RT: In vivo drug discovery in the zebrafish.  Nat
Rev Drug Discov 2005, 4(1):35-44.
35. Cross LM, Cook MA, Lin S, Chen JN, Rubinstein AL: Rapid analysis
of angiogenesis drugs in a live fluorescent zebrafish assay.
Arterioscler Thromb Vasc Biol 2003, 23(5):911-912.
36. Li X, Zhao X, Fang Y, Jiang X, Duong T, Fan C, Huang CC, Kain SR:
Generation of destabilized green fluorescent protein as a
transcription reporter.  J Biol Chem 1998, 273(52):34970-34975.
37. Thermes V, Grabher C, Ristoratore F, Bourrat F, Choulika A, Witt-
brodt J, Joly JS: I-SceI meganuclease mediates highly efficient
transgenesis in fish.  Mech Dev 2002, 118(1-2):91-98.
38. Cooper MS, D'Amico LA: A cluster of noninvoluting endocytic
cells at the margin of the zebrafish blastoderm marks the site
of embryonic shield formation.  Dev Biol 1996, 180(1):184-198.
39. Melby AE, Warga RM, Kimmel CB: Specification of cell fates at the
dorsal margin of the zebrafish gastrula.  Development 1996,
122(7):2225-2237.
40. Hashimoto H, Rebagliati M, Ahmad N, Muraoka O, Kurokawa T, Hibi
M, Suzuki T: The Cerberus/Dan-family protein Charon is a neg-
ative regulator of Nodal signaling during left-right patterning
in zebrafish.  Development 2004, 131(8):1741-1753.
41. Essner JJ, Amack JD, Nyholm MK, Harris EB, Yost HJ: Kupffer's ves-
icle is a ciliated organ of asymmetry in the zebrafish embryo
that initiates left-right development of the brain, heart and
gut.  Development 2005, 132(6):1247-1260.
42. Kramer-Zucker AG, Olale F, Haycraft CJ, Yoder BK, Schier AF, Drum-
mond IA: Cilia-driven fluid flow in the zebrafish pronephros,
brain and Kupffer's vesicle is required for normal organogen-
esis.  Development 2005, 132(8):1907-1921.
43. Long S, Ahmad N, Rebagliati M: The zebrafish nodal-related gene
southpaw is required for visceral and diencephalic left-right
asymmetry.  Development 2003, 130(11):2303-2316.
44. Albertson RC, Yelick PC: Roles for fgf8 signaling in left-right pat-
terning of the visceral organs and craniofacial skeleton.  Dev
Biol 2005, 283(2):310-321.
45. Halpern ME, Liang JO, Gamse JT: Leaning to the left: laterality in
the zebrafish forebrain.  Trends Neurosci 2003, 26(6):308-313.
46. Concha ML, Burdine RD, Russell C, Schier AF, Wilson SW: A nodal
signaling pathway regulates the laterality of neuroanatomical
asymmetries in the zebrafish forebrain.  Neuron 2000,
28(2):399-409.
47. Lun K, Brand M: A series of no isthmus (noi) alleles of the
zebrafish pax2.1 gene reveals multiple signaling events in
development of the midbrain-hindbrain boundary.  Develop-
ment 1998, 125(16):3049-3062.
48. Mohammadi M, McMahon G, Sun L, Tang C, Hirth P, Yeh BK, Hubbard
SR, Schlessinger J: Structures of the tyrosine kinase domain of
fibroblast growth factor receptor in complex with inhibitors.
Science 1997, 276(5314):955-960.
49. Delaune E, Lemaire P, Kodjabachian L: Neural induction in Xeno-
pus requires early FGF signalling in addition to BMP inhibi-
tion.  Development 2005, 132(2):299-310.
50. Maroon H, Walshe J, Mahmood R, Kiefer P, Dickson C, Mason I: Fgf3
and Fgf8 are required together for formation of the otic pla-
code and vesicle.  Development 2002, 129(9):2099-2108.
51. Fong TA, Shawver LK, Sun L, Tang C, App H, Powell TJ, Kim YH,
Schreck R, Wang X, Risau W, Ullrich A, Hirth KP, McMahon G:
SU5416 is a potent and selective inhibitor of the vascular
endothelial growth factor receptor (Flk-1/KDR) that inhibits
tyrosine kinase catalysis, tumor vascularization, and growth
of multiple tumor types.  Cancer Res 1999, 59(1):99-106.
52. Giles FJ, Cooper MA, Silverman L, Karp JE, Lancet JE, Zangari M, Shami
PJ, Khan KD, Hannah AL, Cherrington JM, Thomas DA, Garcia-Man-
ero G, Albitar M, Kantarjian HM, Stopeck AT: Phase II study of
SU5416--a small-molecule, vascular endothelial growth fac-
tor tyrosine-kinase receptor inhibitor--in patients with
refractory myeloproliferative diseases.  Cancer 2003,
97(8):1920-1928.
53. Cross MJ, Claesson-Welsh L: FGF and VEGF function in angio-
genesis: signalling pathways, biological responses and thera-
peutic inhibition.  Trends Pharmacol Sci 2001, 22(4):201-207.
54. Kendall RL, Rutledge RZ, Mao X, Tebben AJ, Hungate RW, Thomas
KA: Vascular endothelial growth factor receptor KDR tyro-
sine kinase activity is increased by autophosphorylation of
two activation loop tyrosine residues.  J Biol Chem 1999,
274(10):6453-6460.
55. Liao AT, Chien MB, Shenoy N, Mendel DB, McMahon G, Cherrington
JM, London CA: Inhibition of constitutively active forms of
mutant kit by multitargeted indolinone tyrosine kinase inhib-
itors.  Blood 2002, 100(2):585-593.
56. Heryanto B, Lipson KE, Rogers PA: Effect of angiogenesis inhibi-
tors on oestrogen-mediated endometrial endothelial cell
proliferation in the ovariectomized mouse.  Reproduction 2003,
125(3):337-346.
57. Strawn LM, McMahon G, App H, Schreck R, Kuchler WR, Longhi MP,
Hui TH, Tang C, Levitzki A, Gazit A, Chen I, Keri G, Orfi L, Risau W,
Flamme I, Ullrich A, Hirth KP, Shawver LK: Flk-1 as a target for
tumor growth inhibition.  Cancer Res 1996, 56(15):3540-3545.
58. Boguslawski G, McGlynn PW, Harvey KA, Kovala AT: SU1498, an
inhibitor of vascular endothelial growth factor receptor 2,
causes accumulation of phosphorylated ERK kinases and
inhibits their activity in vivo and in vitro.  J Biol Chem 2004,
279(7):5716-5724.
59. Arbiser JL, Larsson H, Claesson-Welsh L, Bai X, LaMontagne K, Weiss
SW, Soker S, Flynn E, Brown LF: Overexpression of VEGF 121 in
immortalized endothelial cells causes conversion to slowlyPublish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Developmental Biology 2007, 7:62 http://www.biomedcentral.com/1471-213X/7/62
Page 14 of 14
(page number not for citation purposes)
growing angiosarcoma and high level expression of the VEGF
receptors VEGFR-1 and VEGFR-2 in vivo.  Am J Pathol 2000,
156(4):1469-1476.
60. Boilly B, Vercoutter-Edouart AS, Hondermarck H, Nurcombe V, Le
Bourhis X: FGF signals for cell proliferation and migration
through different pathways.  Cytokine Growth Factor Rev 2000,
11(4):295-302.
61. Kusakabe M, Masuyama N, Hanafusa H, Nishida E: Xenopus FRS2 is
involved in early embryogenesis in cooperation with the Src
family kinase Laloo.  EMBO Rep 2001, 2(8):727-735.
62. Tatton L, Morley GM, Chopra R, Khwaja A: The Src-selective
kinase inhibitor PP1 also inhibits Kit and Bcr-Abl tyrosine
kinases.  J Biol Chem 2003, 278(7):4847-4853.
63. Blake RA, Broome MA, Liu X, Wu J, Gishizky M, Sun L, Courtneidge
SA: SU6656, a selective src family kinase inhibitor, used to
probe growth factor signaling.  Mol Cell Biol 2000,
20(23):9018-9027.
64. Chan J, Bayliss PE, Wood JM, Roberts TM: Dissection of angiogenic
signaling in zebrafish using a chemical genetic approach.  Can-
cer Cell 2002, 1(3):257-267.
65. Lawson ND, Weinstein BM: In vivo imaging of embryonic vascu-
lar development using transgenic zebrafish.  Dev Biol 2002,
248(2):307-318.
66. Lawson ND, Mugford JW, Diamond BA, Weinstein BM: phospholi-
pase C gamma-1 is required downstream of vascular
endothelial growth factor during arterial development.  Genes
Dev 2003, 17(11):1346-1351.
67. Serbedzija GN, Flynn E, Willett CE: Zebrafish angiogenesis: a new
model for drug screening.  Angiogenesis 1999, 3(4):353-359.
68. Du SJ, Dienhart M: Zebrafish tiggy-winkle hedgehog promoter
directs notochord and floor plate green fluorescence protein
expression in transgenic zebrafish embryos.  Dev Dyn 2001,
222(4):655-666.
69. Balciunas D, Davidson AE, Sivasubbu S, Hermanson SB, Welle Z, Ekker
SC: Enhancer trapping in zebrafish using the Sleeping Beauty
transposon.  BMC Genomics 2004, 5(1):62.
70. Sharma D, Holets L, Zhang X, Kinsey WH: Role of Fyn kinase in sig-
naling associated with epiboly during zebrafish development.
Dev Biol 2005, 285(2):462-476.
71. Jopling C, den Hertog J: Fyn/Yes and non-canonical Wnt signal-
ling converge on RhoA in vertebrate gastrulation cell move-
ments.  EMBO Rep 2005, 6(5):426-431.
72. Tsai WB, Zhang X, Sharma D, Wu W, Kinsey WH: Role of Yes
kinase during early zebrafish development.  Dev Biol 2005,
277(1):129-141.
73. Araki I, Brand M: Morpholino-induced knockdown of fgf8 effi-
ciently phenocopies the acerebellar (ace) phenotype.  Genesis
2001, 30(3):157-159.